Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 21 Apr 23 424B3 Prospectus supplement
- 7 Apr 23 424B3 Prospectus supplement
- 31 Mar 23 424B3 Prospectus supplement
- 9 Mar 23 EFFECT Notice of effectiveness
- 8 Mar 23 424B3 Prospectus supplement
- 6 Mar 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 24 Feb 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 9 Feb 23 S-4/A Registration of securities issued in business combination transactions (amended)
-
27 Jan 23 S-4/A Registration of securities issued in business combination transactions (amended)
- 23 Dec 22 S-4 Registration of securities issued in business combination transactions
GRI similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Amendment No. 1 to the Registration Statement of Vallon Pharmaceuticals, Inc. on Form S-4 to be filed on or about January 27, 2023 of our report dated February 14, 2022, on our audits of the financial statements as of December 31, 2021 and 2020 and for each of the years then ended. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern. We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.
/s/ EisnerAmper LLP
EISNERAMPER LLP
Iselin, New Jersey
January 27, 2023